Skip to content
AnalystLens

Thermo Fisher Scientific 8-K Report, Financial Results (Oct 21, 2026)

Reports
Earnings & Results·Exhibits & Filings
Filing Date
Filed October 21, 2026
Period End
October 21, 2026
Security
TMO
In the record · 2016–202610-K1110-Q338-K153

TMO filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 153 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Aug ’17Aug ’17
  2. Material agreement8-K · Oct ’19Oct ’19
  3. Leadership change8-K · Feb ’22Feb ’22
  4. Leadership change8-K · Jan ’26Jan ’26

01—Abstract

Summary

Summary of the 8-K filed October 21, 2026. Cited figures are marked; the original filing is the authoritative source.

Thermo Fisher Scientific Inc. (TMO) reported strong third quarter 2026 financial results on October 21, 2026.

The company achieved a 9% increase in revenue, reaching $12.14 billiona, with a notable 6% driven by organic growth. Both GAAP Diluted Earnings Per Share (EPS) and Adjusted EPS saw significant year-over-year increases, growing 9% to $4.64 and 15% to $6.68, respectively. The company highlighted its successful execution of a proven growth strategy, evidenced by the launch of innovative new products across various segments and strengthened customer partnerships.

Strategic capital deployment was also a focus, including the completion of a business divestiture. Management expressed confidence in delivering an excellent full year 2026, emphasizing continued long-term value creation for stakeholders.

02—Key points

Key Highlights

  1. Third quarter revenue increased 9% year-over-year to $12.14 billion, with 6% organic revenue growth.
  2. GAAP Diluted EPS grew 9% to $4.64, while Adjusted EPS increased 15% to $6.68 for the third quarter.
  3. Significant product launches were highlighted, including the Thermo Scientific Orbitrap Isora mass spectrometer and the EMPAD G2 electron detector.
  4. Strengthened customer relationships and strategic initiatives, such as the Precure partnership with Mayo Clinic, were emphasized.
  5. The company completed the divestiture of its microbiology business during the quarter.
  6. Free cash flow for the nine months ended September 26, 2026, increased to $4.618 billion from $3.319 billion in the prior year period.
  7. Goodwill increased significantly to $54.263 billion from $49.362 billion at the end of 2025, indicating substantial acquisitions.

03—Questions

Frequently Asked Questions

  1. What were Thermo Fisher Scientific's key financial performance metrics for the third quarter of 2026?

    For the third quarter of 2026, Thermo Fisher Scientific reported total revenue of $12.14 billion, a 9% increase compared to the prior year, with 6% driven by organic growth. GAAP Diluted EPS grew 9% to $4.64, and Adjusted EPS rose 15% to $6.68.

  2. What are some of the key growth drivers mentioned by the company?

    The company cited its proven growth strategy, the launch of high-impact innovative products, and the strengthening of its commercial engine and customer partnerships as key growth drivers. Specific examples include new mass spectrometers, electron detectors, diagnostic tests, and sequencing chips.

  3. How did the company's capital deployment activities fare in the third quarter?

    Thermo Fisher Scientific successfully executed its capital deployment strategy by completing the divestiture of its microbiology business during the quarter. The company also noted significant increases in goodwill, suggesting ongoing investment through acquisitions.

  4. What is the company's outlook for the remainder of 2026?

    Management expressed confidence in delivering an excellent full year 2026, stating they are well-positioned to continue driving long-term value creation for all stakeholders.

04—Continue

← View all 8-K filings